Loading…
Silexion Therapeutics Corp is projected to decline to $1.81 by 2027, a -7% move from its current price of $1.95. SLXN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.76 | $1.95 | $2.16 | -0.09% |
| Aug 6 | $1.69 | $1.95 | $2.25 | -0.18% |
| Aug 7 | $1.63 | $1.94 | $2.32 | -0.26% |
| Aug 8 | $1.59 | $1.94 | $2.38 | -0.35% |
| Aug 9 | $1.55 | $1.94 | $2.43 | -0.44% |
| Aug 10 | $1.51 | $1.94 | $2.48 | -0.52% |
| Aug 11 | $1.48 | $1.94 | $2.53 | -0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.48 | $1.94 | $2.53 | -0.61% |
| Week 2 | $1.32 | $1.93 | $2.81 | -1.22% |
| Week 3 | $1.21 | $1.91 | $3.04 | -1.82% |
| Week 4 | $1.12 | $1.90 | $3.25 | -2.42% |
| Week 5 | $1.04 | $1.89 | $3.44 | -3.02% |
| Week 6 | $0.9773 | $1.88 | $3.61 | -3.61% |
| Week 7 | $0.9217 | $1.87 | $3.79 | -4.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Silexion Therapeutics Corp is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. It uses its proprietary LODER delivery platform to treat solid tumors, including SiG12D-LODER which has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer. Its products include Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer, and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN is the stock ticker for Silexion Therapeutics Corp. The current price is $1.84, and the market capitalization is $1.96M, with a rank of 5152. The near-term forecast shows a neutral to mixed path, with 2026 averaging $1.84 (range $1.60-$2.25, ROI 0%, sentiment NEUTRAL) and 2027 averaging $1.73 (range $1.26-$2.57, ROI -5.7%, sentiment NEUTRAL).
Forecasts turn more bullish in 2028, with an average of $2.67 (range $1.83-$4.23, ROI 45.3%, sentiment BULLISH), and continued strength into 2029 ($2.54 avg, range $1.65-$4.22, ROI 37.9%, sentiment BULLISH). The 2030 projection is $2.24 on average (range $1.39-$3.88, ROI 21.6%, sentiment BULLISH), followed by further growth in 2031 ($2.50 avg) and beyond, with long-horizon bulls through 2050 (average $4.91, ROI 166.9%).
A major floor 86.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.9% below — buyers have tended to step in here.
The nearest ceiling, 46.2% above — a clean break opens room to run.
A major ceiling 156.2% above — clearing it would confirm fresh momentum.
Key SLXN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLXN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.06 | Sell | $2.00 | Sell |
| MA 10 | $2.26 | Sell | $2.18 | Sell |
| MA 20 | $2.45 | Sell | $2.36 | Sell |
| MA 50 | $2.77 | Sell | $2.38 | Sell |
| MA 100 | $1.89 | Buy | $2.32 | Sell |
| MA 200 | $2.15 | Sell | $4.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.92 | Neutral |
| Stoch RSI (14) | 33.17 | Neutral |
| CCI (20) | -166.89 | Sell |
| Williams %R (14) | -76.27 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -27.13 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 23.73 | Neutral |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -0.50 | Sell |
| Ultimate (7,14,28) | 33.70 | Neutral |
| Momentum (10) | -0.70 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.73 | Buy |
| ADX (14) | 14.69 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30. The stock trades well below its longer-term averages, with SMA50 at $3.21 and SMA200 at $15.54. Support is indicated at $1.60 and resistance at $2.90. The 30-day price range runs from $0.9284 to $3.65. Annualized volatility is 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.60 | $1.95 | $2.40 | 0% | Neutral | |
| $1.32 | $1.81 | $2.68 | -7% | Neutral | |
| $1.94 | $2.83 | $4.48 | +45% | Bullish | |
| $1.76 | $2.71 | $4.51 | +39% | Bullish | |
| $1.46 | $2.35 | $4.08 | +21% | Bullish | |
| $1.57 | $2.64 | $4.74 | +36% | Bullish | |
| $1.20 | $2.10 | $3.89 | +8% | Neutral | |
| $1.21 | $2.22 | $4.22 | +14% | Neutral | |
| $1.73 | $3.30 | $6.43 | +69% | Bullish | |
| $1.67 | $3.31 | $6.61 | +70% | Bullish | |
| $1.92 | $4.27 | $9.36 | +119% | Bullish | |
| $2.35 | $5.23 | $12.03 | +168% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.60 | $1.95 | $2.33 | +0.00% |
| September 2026 | $1.43 | $1.74 | $2.20 | -10.88% |
| October 2026 | $1.46 | $1.80 | $2.33 | +3.59% |
| November 2026 | $1.52 | $1.89 | $2.49 | +5.07% |
| December 2026 | $1.43 | $1.80 | $2.40 | -4.82% |
Click any year to see its month-by-month SLXN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SLXN is projected to trade between $1.60 and $2.40, averaging $1.95 — a potential gain of 0% from today's $1.95. Price action looks broadly range-bound.
Silexion Therapeutics Corp's 2027 outlook centres on $1.81, within a $1.32 to $2.68 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, SLXN could reach as high as $4.48, with a base case around $2.83 and support toward $1.94 — roughly +45% from $1.95. Momentum favours further upside here.
Expect SLXN to range from $1.76 to $4.51 through 2029. The $2.71 average target implies a +39% move from current prices. That is -4% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The SLXN price prediction for 2030 points to an average of $2.35 (low $1.46, high $4.08) — a potential gain of +21% on today's $1.95. Momentum favours further upside here.
In 2031, SLXN is projected to trade between $1.57 and $4.74, averaging $2.64 — a potential gain of +36% from today's $1.95. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Silexion Therapeutics Corp's 2032 outlook centres on $2.10, within a $1.20 to $3.89 range. That is -20% versus the projected 2031 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2033, SLXN could reach as high as $4.22, with a base case around $2.22 and support toward $1.21 — roughly +14% from $1.95. A consolidation phase looks the most probable path here.
Expect SLXN to range from $1.73 to $6.43 through 2034. The $3.30 average target implies a +69% move from current prices. That is up +49% on the projected 2033 average. Momentum favours further upside here.
The SLXN price prediction for 2035 points to an average of $3.31 (low $1.67, high $6.61) — a potential gain of +70% on today's $1.95. Buyers look set to stay in control over this stretch.
In 2040, SLXN is projected to trade between $1.92 and $9.36, averaging $4.27 — a potential gain of +119% from today's $1.95. That is up +29% on the projected 2035 average. Momentum favours further upside here.
Silexion Therapeutics Corp's 2050 outlook centres on $5.23, within a $2.35 to $12.03 range. That is up +22% on the projected 2040 average. That marks a +168% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLXN today (≈ 512.820513 SLXN) could be worth
$2,681.47
+$1,681.47 (+168%) by 2050 · US Dollar
Based on the average projected SLXN price of $5.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLXNwould be worth at today's price.
$1,000 invested in SLXN on Jul 31, 2025 (≈ 66.934406 SLXN) would be worth
$130.52
-$869.48 (-86.9%) today · 0.13× · US Dollar
Based on a SLXN entry price of $14.94 vs. today's $1.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.27 | $859.03 | -14.1% |
| 1 month ago | $2.59 | $754.35 | -24.6% |
| 3 months ago | $0.598 | $3,260.87 | +226.1% |
| 6 months ago | $1.8 | $1,083.33 | +8.3% |
| 1 year ago | $14.94 | $130.52 | -86.9% |
| All time (5.0y) ago | $145.05 | $13.44 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLXN forecast.
Our base-case forecast reaches $3.90 around 2040.
Implied market cap at $3.90: $4.15M
The long-range forecast shows a bullish trajectory beginning in 2028 and extending through 2050. The 2026-27 period is assessed as NEUTRAL, with 2026 averaging $1.84 and 2027 averaging $1.73. From 2028 onward, the outlook turns BULLISH, with 2028 averaging $2.67 and a 45.3% ROI, 2029 averaging $2.54 (ROI 37.9%), and 2030 averaging $2.24 (ROI 21.6%).
Notable later-year medians include 2031 at $2.50 (ROI 35.8%), 2034 at $3.13 (ROI 70.1%), 2035 at $3.11 (ROI 69.1%), 2040 at $4.04 (ROI 119.4%), and 2050 at $4.91 (ROI 166.9%). The sentiment strengthens to BULLISH across most of the forecast horizon, though these are estimates, not guarantees.
Tap a question to reveal the answer.
Avg price $2.24; min $1.39; max $3.88; ROI 21.6%; sentiment BULLISH.
Near-term forecasts show NEUTRAL in 2026 and 2027, then BULLISH from 2028 onward with 2028 avg $2.67 (ROI 45.3%), 2029 avg $2.54 (ROI 37.9%), 2030 avg $2.24 (ROI 21.6%). Longer-term ROIs reach 119.4% in 2040 and 166.9% in 2050.
Yes. The forecast maximums include $6.10 in 2034 and $6.21 in 2035.
Current price is $1.84. Market cap is $1.96M, and the rank is 5152.
30-day range is from $0.9284 to $3.65. RSI14 is 30, indicating bearish momentum. Annualized volatility is 200%.
Silexion Therapeutics Corp Community Discussion
0Share your Silexion Therapeutics Corp price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.